Submission of quarterly results for the quarter ended 30th June, 2025 pursuant to the Regulation 33 of SEBI (LODR) Regulations, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories (formerly Macro International) reported Q1 FY26 revenue from operations of Rs. 2,532.66 lakhs, nearly doubling from Rs. 1,314.57 lakhs in the same quarter last year (around 93% YoY growth). Total revenue stood at Rs. 2,538.27 lakhs versus Rs. 1,317.99 lakhs previously. Profit after tax grew to Rs. 208.96 lakhs from Rs. 168.91 lakhs (~24% YoY), translating to a basic EPS of Rs. 2.13 versus Rs. 1.72. However, total expenses more than doubled (Rs. 2,259 lakhs vs Rs. 1,084 lakhs), with finance costs jumping sharply to Rs. 30.08 lakhs from Rs. 6.29 lakhs, which pushed EBITDA margins down meaningfully. The auditor (Sathuluri & Co) issued a clean limited review report with no qualifications or emphasis matters. The company operates a single segment in active pharmaceutical ingredients (bulk drugs).
Strong topline growth is a positive signal, but rising costs and sharply higher finance charges compressed margins, keeping profit growth well below revenue growth. Shareholders should watch whether the margin pressure persists in coming quarters and what is driving the increase in interest costs.